PHYSICIAN RESOURCES:
Monoclonal Antibodies (mAbs)
The largest hurdles faced by Health Care Providers (HCPs) and patients seeking mAb infusion is a transparent process and clear communication about how to gain access to treatment.
We have researched multiple programs set up by facilities around the country, spoken to hospitals and health departments, and navigated the process for physicians and patients alike.
Our work has resulted in the following resources, based on the best practices we have seen to date, to help medical facilities set up seamless infusion programs that support HCPs.
Together we can get treatment into newly diagnosed COVID patients as quickly as possible.
This search engine displays public locations that have received shipments of U.S. Government-procured COVID-19 therapeutics under FDA Emergency Use Authorization (EUA). (The locations in the locator have reported stock on hand within the last day.)
Monoclonal antibody treatment Evusheld (Astra Zeneca), and the oral antiviral therapies Paxlovid (Pfizer), and Molnupiravir (Merck) have been authorized for either treatment or prevention.
